Condition: Melanoma · Squamous Cell Carcinoma of Head and Neck · Sponsor: IO Biotech
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.
This description comes directly from the study's public registry record.
Diane McDowell SVP, Clinical Development and Medical Affairs, MD · +1 267 252 7296 · dmd@iobiotech.com
Shane O'Neill Clinical Program Director · +44 790 433 7285 · son@iobiotech.com
Always discuss trial participation with your own doctor first.
| Yale | New Haven, Connecticut, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Massey Cancer Center | Richmond, Virginia, United States | Recruiting |
| Melanoma Institute Australia The Uiniversity of Sydney, and Royal North Shore Hospital | Sydney, New South Wales, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Copenhagen University Hospital Herlev | Copenhagen, Denmark | Recruiting |
| CHRU Lille | Lille, France | Recruiting |
| Hôpital Ambroise-Paré | Paris, France | Recruiting |
| Institut Gustave Roussy | Paris, France | Recruiting |
| Universitätsklinikum Essen & Research Alliance Ruhr | Essen, Germany | Recruiting |
| Universität Heidelberg, Medizinische Fakultät | Heidelberg, Germany | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05280314